Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model | Zendy

Alexander J. Lepak | Zendy; Miao Zhao | Zendy; David R. Andes | Zendy

Open Access

Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model

Author(s) -

Alexander J. Lepak,

Miao Zhao,

David R. Andes

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01556-19

Subject(s) - candida dubliniensis , echinocandin , candida tropicalis , pharmacodynamics , candida parapsilosis , pharmacokinetics , microbiology and biotechnology , area under the curve , biology , pharmacology , dosing , fluconazole , candida albicans , medicine , antifungal , corpus albicans

Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (i.v.) dosing. We evaluated the pharmacodynamics (PD) of rezafungin against 4Candida tropicalis and 4Candida dubliniensis strains, using the neutropenic mouse invasive candidiasis model. The area under the concentration-time curve (AUC)/MIC was a robust predictor of efficacy (R 2 = 0.93 and 0.72, respectively).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research